N-of-One Secures $7 Million in Series B financing
![](/46/pdcnewsitem/04/18/66/nofone.png)
The financing will be used to expand the company's leading precision medicine decision support solutions in oncology.
N-of-One has received $7 million in a Series B financing from Providence Ventures and Excel Venture Management. The financing will be used to expand the company’s R&D efforts to broaden its precision medicine clinical decision support solutions in oncology, providing physicians with a precise and scalable approach to matching patients to the most relevant treatments including clinical trials. N-of-One will also expand sales and marketing in the US and strategic global markets.
“This financing round marks a new and exciting chapter for N-of-One, and we are pleased to partner with Providence Ventures and Excel Venture Management to take the next step in solving the growing complexity of precision medicine. We look forward to collaborating with our lab and health system clients to incorporate clinical data along with the patient’s molecular profile to provide further refinement of treatment options. This is particularly important given the growing complexity of clinical trial eligibility criteria,” said Chris Cournoyer, CEO of N-of-One.
“Cancer treatment is not one size fits all, and finding the right treatment, to include appropriate clinical trials, as quickly as possible, is a top priority,” said Thomas Brown, executive director of the Swedish Cancer Institute and co-chair of Providence Health & Services’ Personalized Medicine Program. “We are thrilled to be expanding our relationship with N-of-One to scale molecular oncology decision making, bringing the promise of precision medicine to thousands of cancer patients.”
“We are delighted to be investors in N-of-One with its unrivaled technology for assisting physicians in determining the optimal treatment for their cancer patients in this era of personalized medicine,” commented board member Steve Gullans of Excel.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance